Endo Itsuro, Matsumoto Toshio
Division of Endocrinology and Metabolism, The University of Tokushima Hospital, Japan.
Clin Calcium. 2012 Mar;22(3):327-33.
Daily subcutaneous self-injection and weekly subcutaneous injection formulas of teriparatide are available as anabolic agents in Japan. These injection formulas are expected to serve as a new treatment choice for high fracture-risk patients with osteoporosis. In addition, studies using new anabolic agents such as PTHrP, calcilytics, and Wnt inhibitor antagonists/antibodies are under way to develop new anabolic agents. These agents may become new treatment drugs for osteoporotic patients especially with low bone turnover.
在日本，特立帕肽的每日皮下自我注射和每周皮下注射配方作为促合成代谢药物可供使用。这些注射配方有望成为骨质疏松症高骨折风险患者的一种新的治疗选择。此外，正在开展使用甲状旁腺激素相关蛋白（PTHrP）、钙敏感受体阻滞剂和Wnt抑制剂拮抗剂/抗体等新型促合成代谢药物的研究，以开发新型促合成代谢药物。这些药物可能成为尤其是骨转换率低的骨质疏松症患者的新型治疗药物。
